GAL-021 is primarily investigated for its potential therapeutic applications in respiratory disorders. It functions as a modulator of the carotid body, which plays a crucial role in regulating breathing by sensing oxygen and carbon dioxide levels in the blood. This compound has shown promise in enhancing respiratory drive, making it a candidate for treating conditions like opioid-induced respiratory depression, a serious side effect of opioid use that can lead to life-threatening breathing suppression. Additionally, GAL-021 is being explored for its utility in managing sleep apnea, particularly in cases where patients exhibit inadequate respiratory responses during sleep. Its ability to stimulate breathing without significant side effects positions it as a potential alternative or adjunct to existing respiratory stimulants. Research is ongoing to further validate its efficacy and safety in clinical settings.